Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.69 |
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.69 |
| ▸ | ALPL | P05186 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454144 | 0.90 | SMN1; SMN2 (0.60) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL5959950 | 0.85 | SMN1; SMN2 (0.69) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL8311588 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL6449632 | 0.79 | JAK2 (0.56) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL4186276 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL4552315 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL6452334 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL5325012 | 0.76 | KDM4E (0.59) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL6449955 | 0.75 | JAK2 (0.49) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL18292526 | 0.75 | L3MBTL1 (0.77) | SMN1; SMN2TDP1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | claimed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SMN1; SMN2 1279/4885TDP1 3341/4885L3MBTL1 4123/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | SMN1; SMN2 4633/4885TDP1 4550/4885L3MBTL1 4366/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SMN1; SMN2 1279/4885TDP1 3341/4885L3MBTL1 4123/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | SMN1; SMN2 1279/4885TDP1 3341/4885L3MBTL1 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.